Quince Therapeutics Regains Nasdaq Compliance for Stockholders' Equity Rule
QNCX sits 32% above its 52-week low of $0.79 on light trading volume (0.2× avg).
Summary
Quince Therapeutics announced it has regained compliance with a key Nasdaq listing rule regarding stockholders' equity, resolving a previous delisting concern.
Key Events · Corporate Governance and Compliance · QNCX
-
Regains Nasdaq Compliance
The company received a letter from Nasdaq confirming compliance with Rule 5450(b)(1)(A) (minimum stockholders' equity of $10 million), based on its Q1 2026 report of $15.672 million.
-
Resolves Prior Delisting Threat
This action closes the previously disclosed non-compliance issue regarding the minimum market value of listed securities (Rule 5450(b)(2)(A)), removing an immediate delisting risk.
-
Ongoing Compliance Challenges
Despite this resolution, the company continues to face other Nasdaq compliance issues, including the bid price rule, and has proposed a more aggressive reverse stock split (up to 1-for-100) to address these.
Analysis · QNCX · Life Sciences
This filing confirms Quince Therapeutics has regained compliance with Nasdaq's minimum stockholders' equity requirement (Rule 5450(b)(1)(A)), based on its Q1 2026 financial report. This resolves a previously disclosed non-compliance issue related to market value of listed securities and removes an immediate delisting threat. However, the company still faces other Nasdaq compliance challenges, including the bid price rule, and has proposed a more aggressive reverse stock split to address these.
At the time of this filing, QNCX was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.79 to $45.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.